Latest $2.5M renewal continues NCI grant for 17 years
The T32-Ruth L. Kirschstein National Research Service Award Institutional Training Grant supports pre- and post-doctoral training in cancer therapeutics
University of Cincinnati (UC) College of Medicine researchers have received $2.5 million for renewal of a highly competitive grant from the National Cancer Institute to support pre- and post-doctoral training in cancer therapeutics—a branch of medicine that applies scientific knowledge to develop more effective treatment of human diseases.
This will make 17 years in counting that the grant—the T32-Ruth L. Kirschstein National Research Service Award Institutional Training Grant—will fund programs at UC through co-principal investigators Susan Waltz, PhD, and Carolyn Price, PhD, professors in the Department of Cancer Biology.
"This grant, titled ‘Pathways to Cancer Therapeutics,’ will continue supporting the Training Program in Cancer Therapeutics, a postdoctoral and graduate student training program,” says Waltz, who is also a member of the Cincinnati Cancer Center and UC Cancer Institute. "This program offers trainees the benefit of faculty mentorship from basic researchers and clinician-scientists, as well as career development opportunities and practical learning experiences with mentors in over 12 departments across the UC College of Medicine and Cincinnati Children’s.
"Our emphasis is on training the next generation of cancer researchers to translate basic science discoveries into improved patient care.”
Carolyn Price, PhD
Waltz says, since receiving initial funding in 2008, the T32 has supported 42 trainees—10 predoctoral fellows and 32 postdoctoral fellows—and that over 150 papers have been published by trainees as a result of the support. This renewal will support up to eight additional trainees annually.
"As a result of the T32 funding, trainees are provided salary support as well as a number of workshops, career activities and courses to complement their research experiences and to make them more competent and competitive cancer biologists,” she adds. "As part of the training program, the trainees also apply for their own external funding. In doing so, 16 extramural grants have been obtained by the trainees including prestigious fellowships from the National Institutes of Health, American Cancer Society, Department of Defense and the American Heart Association. Not only does the training grant provide resources to support trainees but also provides the training to catapult the trainees to early career success in garnering their own funding—and multiplying the extramural research dollars to the university.”
Price adds that a number of past trainees have obtained leadership positions in academia and industry.
"This training serves as an important springboard for young scientists to secure funding and professional cancer research positions,” she adds.
Each cancer therapeutics program trainee is partnered with a scientific and clinical faculty mentor to facilitate collaboration in a defined interest area related to cancer biology. Applications to the program are accepted and evaluated on an ongoing basis. More information is available at cancerbiology.uc.edu or by contacting Waltz at susan.waltz@uc.edu.
Related Stories
Recent advances may speed time to endometriosis diagnosis
March 16, 2026
The average time to clinical diagnosis of endometriosis is nine years. Definitive diagnosis of the disease is difficult, and until recently, has relied on laparoscopic surgery. Now, as Medscape recently reported, novel clinical recommendations, advanced diagnostic tools and research into inflammation and immune responses, are bringing promise that women with endometriosis will find relief sooner and without surgery, according to experts, including Katie Burns, PhD, University of Cincinnati College of Medicine associate professor.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.